News
Get the latest market insights
Stay up to date with Carbon’s expert perspectives, company news and the latest on the pipeline of novel cell and gene therapies that present profound financial implications for payors.
Follow us on LinkedIn for ongoing updates.
FDA Approves World’s First CRISPR-Based Medicine For Sickle Cell
The Food and Drug Administration on Friday approved the world’s first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease that delivers…
Wellness Program RESET: What Employers Should Expect From Vendors
A recent report published by McKinsey estimates that poor health costs the U.S. economy about $3.2 trillion annually from premature deaths and the lost…
Sequoia and IOA Re Announce Expansion Into Personal Accident Reinsurance
Conshohocken, PA, October 24, 2023 – Sequoia Reinsurance Services and IOA Re are pleased to announce a collaboration with Everest Reinsurance Company (“Everest”) and/or its affiliates to expand their…
Mesoblast Plans New GvHD Trial After Another FDA Rejection
Mesoblast plans to conduct a new trial for evaluating the efficacy of remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (GvHD),…
FDA Blesses CellTrans’ Lantidra
Much attention has been paid to Vertex’s efforts to develop a stem cell therapy for Type 1 diabetes. But flying under the radar with…
BioMarin Finally Secures FDA Approval of Hemophilia Gene Therapy
After a prolonged journey, the medicine, known as Roctavian, is now cleared for certain patients with hemophilia A, the more common form of the…
Employers Prioritize Behavioral Health
On the topic of mental health, Jakki Lynch, Carbon Stop Loss Solutions’ Director of Cost Containment, advises, “The key message for health plans is…
FDA Approves Krystal Gene Therapy For Rare Wound Disorder
The Food and Drug Administration on Friday approved the first topical gene therapy, clearing a treatment developed by Krystal Biotech for a rare genetic skin…
U.S. Allows Use of Gamida’s Therapy in Blood Cancer Treatment
The U.S. Food and Drug Administration said on Monday it had approved the use of Gamida Cell Ltd's (GMDA.O), opens new tab cell therapy for…
Novacore Acquires Three Companies to Establish Medical Stop Loss and Managed Care Platform
NSM acquires three companies to bolster its portfolio of leading specialty insurance productsCONSHOHOCKEN, PA, March 20, 2023 – NSM Insurance Group, the nation’s leading specialty insurance…
Ferring Receives Approval from U.S. FDA for Adstiladrin
Ferring’s novel adenovirus vector-based gene therapy Adstiladrin® (nadofaragene firadenovec-vncg) is the first gene therapy approved for bladder cancer.
Inflation Impacts Healthcare Costs and Self-Insured Benefit Plans
The impact of inflation on the broader economy will likely lead to rising healthcare claim costs in an already inflated high price market. Carbon…
Australia’s CSL Prices Hemophilia Gene Therapy at $3.5M
Australian drugmaker CSL Ltd (CSL.AX), opens new tab on Tuesday set the list price of its one-time gene therapy for hemophilia B at $3.5…
Bluebird Wins FDA Approval of Gene Therapy For Rare Brain Disorder
The Food and Drug Administration on Friday granted accelerated approval to a personalized gene therapy for an ultra-rare childhood brain disease, called cerebral adrenoleukodystrophy…
Stop Loss Companies and Reinsurers Help Employers Tackle Key Challenges
The high cost of healthcare claims is just one of several market challenges facing self-insured employers today. The cost of preventable hospital-acquired conditions adds…
Bluebird’s $2.8M Gene Therapy Becomes Most Expensive Drug
The U.S. Food and Drug Administration on Wednesday approved bluebird bio's (BLUE.O), opens new tab gene therapy for patients with a rare disorder requiring…
Bristol’s Breyanzi Wins Broader FDA Nod, Bringing CAR-T Showdown
The FDA has cleared Bristol Myers’ Breyanzi to treat newly relapsed or refractory large B-cell lymphoma (LBCL). The nod comes less than three months after Yescarta became first…
Medicaid Best Price 101
The lowest price available from the manufacturer during the rebate period to any wholesaler, retailer, provider, health maintenance organization, nonprofit entity, or governmental entity…
Yescarta Receives U.S. FDA Approval
Landmark ZUMA-7 Study Demonstrated Patients on Yescarta Were 2.5 Times More Likely to Be Alive at Two Years Without Cancer Progression or Need for…
Carbon Stop Loss Solutions services are provided by IOA Re, LLC (NPN #2006648) and Sequoia Reinsurance Services, LLC (NPN #18853752). Rockport Benefits operates as a division of IOA Re, LLC.